Published in Am J Transplant on May 01, 2006
The TRAIL to viral pathogenesis: the good, the bad and the ugly. Curr Mol Med (2009) 0.89
Embelin prevents LMP1-induced TRAIL resistance via inhibition of XIAP in nasopharyngeal carcinoma cells. Oncol Lett (2016) 0.78
The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases. Antiinfect Agents Med Chem (2009) 0.77
Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology (1996) 1.89
Sequence and analysis of chromosome 1 of the plant Arabidopsis thaliana. Nature (2000) 1.85
Apoptosis as a mechanism of cell death in liver allograft rejection. Transplantation (1995) 1.81
Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl Surg (1998) 1.53
MicroRNAs as immune regulators: implications for transplantation. Am J Transplant (2010) 1.16
An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation (1995) 1.13
Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol (1997) 1.12
Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J Exp Med (1995) 1.11
Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepatology (1995) 0.99
Differential expression of microRNAs during allograft rejection. Am J Transplant (2012) 0.98
Radiolabeled annexin V imaging: diagnosis of allograft rejection in an experimental rodent model of liver transplantation. Radiology (2000) 0.97
Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. Transplant Proc (1995) 0.96
Reduction in HLA-DR, HLA-DQ and HLA-DP expression by Leu-M3+ cells from the peripheral blood of patients with thermal injury. Clin Exp Immunol (1989) 0.92
Evidence for a nonclassical pathway of graft rejection involving interleukin 5 and eosinophils. Transplantation (1993) 0.91
Apoptosis and allograft rejection in the absence of CD8+ T cells. Transplantation (2001) 0.90
Molecular definitions, autoepitopes, and enzymatic activities of the mitochondrial autoantigens of primary biliary cirrhosis. Semin Liver Dis (1989) 0.90
Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphomas is due to defects in the proximal Fas signaling pathway. J Immunol (2001) 0.90
Expression of cytokines and immune mediators during chronic liver allograft rejection. Transplantation (1995) 0.89
Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver (2001) 0.88
Intragraft cytokine profile during human liver allograft rejection. Transplantation (1992) 0.88
Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immunopathol (1996) 0.88
Differential patterns of circulating intercellular adhesion molecule-1 (cICAM-1) and vascular cell adhesion molecule-1 (cVCAM-1) during liver allograft rejection. Transplantation (1995) 0.88
Characterization of allograft rejection in an experimental model of small intestinal transplantation. J Gastrointest Surg (1999) 0.87
Activation of the JAK/STAT pathway in Epstein Barr virus+-associated posttransplant lymphoproliferative disease: role of interferon-gamma. Am J Transplant (2009) 0.85
Viral and immunologic aspects of Epstein-Barr virus infection in pediatric liver transplant recipients. Transplantation (1995) 0.85
Acute liver allograft rejection in the rat. An analysis of the immune response. Transplantation (1995) 0.84
Altered monocyte function in uremia. Clin Immunol Immunopathol (1990) 0.84
Apoptosis as a mechanism of tissue injury in liver allograft rejection. Semin Liver Dis (1998) 0.83
Effect of functional overload on enzyme levels in different types of skeletal muscle. J Appl Physiol Respir Environ Exerc Physiol (1977) 0.83
CD8+ cells are not necessary for allograft rejection or the induction of apoptosis in an experimental model of small intestinal transplantation. J Immunol (1998) 0.83
CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation (1998) 0.81
PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas. Am J Transplant (2013) 0.81
Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. Transplantation (1998) 0.79
IL-2 and IL-5 gene expression in response to alloantigen in liver allograft recipients and in vitro. Transplantation (1993) 0.79
Expression of the cytotoxic T cell mediator granzyme B during liver allograft rejection. Transpl Immunol (1995) 0.79
Application of in situ hybridization technique for quantitative assessment of ongoing symptomatic Epstein-Barr virus infection after living related liver transplantation. Clin Transplant (1998) 0.78
Interleukin-12: a possible cytotoxic T-lymphocyte differentiation factor in allograft recipients. Transplant Proc (1995) 0.78
Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder. Am J Transplant (2013) 0.78
Significance of detecting Epstein-Barr-specific sequences in the peripheral blood of asymptomatic pediatric liver transplant recipients. Liver Transpl (2000) 0.78
Cytokines are involved in the rejection of small intestine allografts. Transplant Proc (1997) 0.77
Human hepatocytes produce an isoform of FAS that inhibits apoptosis. Transplantation (1998) 0.77
Apoptosis as a mechanism of cell death in a rat model of liver allograft rejection. Transplant Proc (1995) 0.77
Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts. Transplantation (1996) 0.77
Involvement of Fas-Fas ligand interactions in graft rejection. Int Rev Immunol (1999) 0.76
Acute rejection of small intestine allografts is associated with increased expression of toll-like receptors. Transplant Proc (2010) 0.75
Circulating intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in pediatric liver recipients. Transplant Proc (1995) 0.75
Epstein-Barr virus infection is associated with endothelial Bcl-2 expression in transplant liver allografts. Transplantation (2002) 0.75
T cell receptor usage by cytotoxic T lymphocytes against autologous human melanoma. Anticancer Res (1997) 0.75
Enzymatic changes in hypertrophied fast-twitch skeletal muscle. Pflugers Arch (1976) 0.75
Characterization of cytokine expression in an animal model of acute liver allograft rejection. Transplant Proc (1995) 0.75
Intragraft eosinophilia and interleukin-5 mRNA accompany liver allograft rejection. Transplant Proc (1993) 0.75
New immunologic insights into mechanisms of allograft rejection. Gastroenterol Clin North Am (1993) 0.75
T-cell receptor-V alpha gene use in sequential liver allograft biopsies. Transplant Proc (1993) 0.75
MHC expression on human hepatocytes before and after isolation. Transplant Proc (1991) 0.75
Elevated biliary interleukin 5 as an indicator of liver allograft rejection. Transpl Immunol (1995) 0.75
Long-term nonresponsiveness to a liver allograft may be cytokine mediated. Transplant Proc (1995) 0.75
Distinct patterns of Th2 cytokine production during immune activation in pediatric liver allograft recipients. Transplant Proc (1995) 0.75